4-(((methoxycarbonyl)amino)methyl)benzoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(((methoxycarbonyl)amino)methyl)benzoic acid
• 英文别名: 4-Carbomethoxyaminomethyl benzoic acid；4-[(methoxycarbonylamino)methyl]benzoic acid
• 化学式: C₁₀H₁₁NO₄
• mdl: MFCD11129019
• 分子量: 209.202
• InChiKey: MNAOAODRIGCCED-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-氨甲基苯甲酸 、 氯甲酸甲酯 以 1,4-二氧六环 、 N,N-二甲基乙酰胺 为溶剂， 生成 4-(((methoxycarbonyl)amino)methyl)benzoic acid
  参考文献：
  名称：

  [EN] FACTOR XIa INHIBITORS
  [FR] INHIBITEURS DU FACTEUR XIA

  摘要：

  本发明提供了一种化合物(I)及包含一种或多种所述化合物的药物组合物，以及使用所述化合物用于治疗或预防血栓、栓塞、高凝血性或纤维变化的方法。这些化合物是选择性因子XIa抑制剂或因子XIa和血浆激肽原的双重抑制剂。

  公开号：

  WO2015164308A1

文献信息

• PRODRUGS OF OPIOIDS AND USES THEREOF
  申请人：Franklin Richard

  公开号：US20110190267A1

  公开（公告）日：2011-08-04

  The present invention concerns prodrugs of opioid analgesics and pharmaceutical compositions containing such prodrugs. Methods for providing more consistent pain relief by increasing the bioavailability of the opioid analgesic with the aforementioned prodrugs are provided. The invention also provides for decreasing the adverse GI side effects of opioid analgesics.

  本发明涉及阿片类镇痛药的前药以及含有此类前药的药物组合物。本发明提供了通过前述前药增加阿片类镇痛药的生物利用度，从而提供更一致的疼痛缓解方法。该发明还提供了减少阿片类镇痛药对胃肠道的副作用的方法。
• Pyridyl derivatives as histone deacetylase inhibitors
  申请人：Heidebrecht, Jr. Richard W.

  公开号：US08461189B2

  公开（公告）日：2013-06-11

  The present invention relates to a novel class of pyridyl and pyrimidinyl derivatives. The pyridyl and pyrimidinyl compounds can be used to treat cancer. The pyridyl and pyrimidinyl compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the pyridyl and pyrimidinyl derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the pyridyl and pyrimidinyl derivatives in vivo.

  本发明涉及一种新型的吡啶基和嘧啶基衍生物。这些吡啶基和嘧啶基化合物可用于治疗癌症。这些吡啶基和嘧啶基化合物还可以抑制组蛋白去乙酰化酶，并适用于选择性诱导末端分化，阻止肿瘤细胞的生长和/或凋亡，从而抑制这些细胞的增殖。因此，本发明的化合物可用于治疗具有肿瘤细胞增殖特征的患者。本发明的化合物也可用于预防和治疗TRX介导的疾病，如自身免疫性、过敏性和炎症性疾病，以及中枢神经系统（CNS）疾病的预防和/或治疗，如神经退行性疾病。本发明还提供了包含这些吡啶基和嘧啶基衍生物的药物组合物以及这些药物组合物的安全剂量方案，这些方案易于遵循，并在体内产生治疗有效量的吡啶基和嘧啶基衍生物。
• PYRIDYL AND PYRIMIDINYL DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS
  申请人：Heidebrecht, JR. Richard W.

  公开号：US20100324092A1

  公开（公告）日：2010-12-23

  The present invention relates to a novel class of pyridyl and pyrimidinyl derivatives. The pyridyl and pyrimidinyl compounds can be used to treat cancer. The pyridyl and pyrimidinyl compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the pyridyl and pyrimidinyl derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the pyridyl and pyrimidinyl derivatives vivo.

  本发明涉及一种新型的吡啶基和嘧啶基衍生物。这些吡啶基和嘧啶基化合物可用于治疗癌症。这些吡啶基和嘧啶基化合物还可以抑制组蛋白去乙酰化酶，并适用于选择性诱导末端分化，阻止肿瘤细胞生长和/或凋亡，从而抑制这些细胞的增殖。因此，本发明的化合物在治疗具有肿瘤细胞增殖特征的患者中非常有用。本发明的化合物也可用于预防和治疗TRX介导的疾病，如自身免疫、过敏和炎症性疾病，以及中枢神经系统（CNS）疾病的预防和/或治疗，如神经退行性疾病。本发明还提供了包含吡啶基和嘧啶基衍生物的药物组合物和这些药物组合物的安全剂量方案，易于遵循，并在体内产生治疗有效量的吡啶基和嘧啶基衍生物。
• Factor XIa inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10093683B2

  公开（公告）日：2018-10-09

  The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more compounds of Formula (I), and methods for using the compounds of Formula (I) for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

  本发明提供了一种式 (I) 的化合物 和包含一种或多种式（I）化合物的药物组合物，以及使用式（I）化合物治疗或预防血栓形成、栓塞、高凝状态或纤维化变化的方法。这些化合物是选择性因子 XIa 抑制剂或因子 XIa 和血浆球蛋白的双重抑制剂。
• CETP INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP1973889B1

  公开（公告）日：2016-08-24